SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

被引：0
|
作者：
Boni, V. [1 ]
Alemany, C. [2 ]
Meisel, J. L. [3 ]
Sinha, R. [4 ]
Sterrenberg, D. [5 ]
Tkaczuk, K. H. R. [6 ]
Wang, Y. [7 ]
Wang, Z. [8 ]
Han, H. S. [9 ]
机构：
[1] Hosp Univ HM Sanchinarro, Ctr Integral Oncol Clara Campal, Madrid, Spain
[2] Canc Inst Florida, AdventHlth Med Grp, Orlando, FL USA
[3] Winship Canc Inst, Dept Hematol Med Oncol, Atlanta, GA USA
[4] Piedmont Canc Inst, Atlanta, GA USA
[5] Ingalls Mem Hosp, Ingalls Canc Care, Harvey, ND USA
[6] Univ Maryland, Dept Med, Ctr Canc, Greenbaum Comprehens Canc Ctr, Baltimore, MD 21201 USA
[7] Seattle Genet Inc, Biostat, Bothell, WA USA
[8] Seattle Genet Inc, Clin Res, Bothell, WA USA
[9] H Lee Moffitt Canc Ctr & Res Inst, Dept Breast Oncol, Tampa, FL USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
196TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The overall survival data of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer, an open-label, single-arm, phase II trial
    Wang, Z.
    Chen, L.
    Fan, L.
    Shao, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S361
  • [42] KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
    Rugo, Hope
    Llombart-Cussac, Antonio
    Andre, Fabrice
    Robson, Mark E.
    Saji, Shigehira
    Harbeck, Nadia
    Schmid, Peter
    Cescon, David
    Ahn, Jin Seok
    Nanda, Rita
    Fan, Li
    Mejia, Jaime Alberto
    Karantza, Vassiliki
    Bardia, Aditya
    CANCER RESEARCH, 2021, 81 (04)
  • [43] Silmitasertib (CX-4945) in combination with gemcitabine and cisplatin as first-line treatment for patients with locally advanced or metastatic cholangiocarcinoma: A phase Ib/II study.
    Borad, Mitesh J.
    Bai, Li-Yuan
    Chen, Ming-Huang
    Hubbard, Joleen M.
    Mody, Kabir
    Rha, Sun Young
    Richards, Donald A.
    Davis, Lindsey S.
    Soong, John
    Huang, Chi-En C-E
    Tse, Emmett
    Ahn, Daniel H.
    Chang, Heung-Moon
    Yen, Chia-Jui
    Oh, Do-Youn
    Park, Joon Oh
    Hsu, Chiun
    Becerra, Carlos Roberto
    Chen, Jen-Shi
    Chen, Yen-Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [44] Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: Prclineinary results report of a phase II trial
    Wang, Z.
    Hu, X.
    Chen, L.
    Wang, J.
    Wang, H.
    Wang, L.
    Liu, G.
    Hu, Z.
    Wu, J.
    Zhimin, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
    Cartwright, TH
    Lopez, T
    Vukelja, SJ
    Encarnacion, C
    Boehm, KA
    Asmar, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 284S - 284S
  • [46] Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
    McDermott, David F.
    Lee, Jae-Lyun
    Bjarnason, Georg A.
    Larkin, James M. G.
    Gafanov, Rustem A.
    Kochenderfer, Mark D.
    Jensen, Niels Viggo
    Donskov, Frede
    Malik, Jahangeer
    Poprach, Alexandr
    Tykodi, Scott S.
    Alonso-Gordoa, Teresa
    Cho, Daniel C.
    Geertsen, Poul F.
    Climent Duran, Miguel Angel
    DiSimone, Christopher
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Schloss, Charles
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (09) : 1020 - 1028
  • [47] Masitinib plus carboplatin and gemcitabine for treatment of patients with advanced triple negative breast cancer: An open label phase Ib/II trial.
    Campone, Mario
    Ferrero, Jean-Marc
    Gunzer, Katharina
    Priou, Frank
    Dubreuil, Patrice
    Mansfield, Colin
    Moussy, Alain
    Hermine, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study
    Demetri, George D.
    Le Cesne, Axel
    Chawla, Sant P.
    Brodowicz, Thomas
    Maki, Robert G.
    Bach, Bruce A.
    Smethurst, Dominic P.
    Bray, Sarah
    Hei, Yong-jiang
    Blay, Jean-Yves
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (04) : 547 - 563
  • [49] Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)
    Schmid, Peter
    Cortes, Javier
    Robson, Mark
    Iwata, Hiroji
    Hegg, Roberto
    Verma, Sunil
    Nechaeva, Marina
    Xu, Binghe
    Haddad, Vincent
    Imedio, Esteban Rodrigo
    Schiavon, Gaia
    Foxley, Andrew
    Park, Yeon Hee
    CANCER RESEARCH, 2020, 80 (04)
  • [50] A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).
    Schmid, Peter
    Cortes, Javier
    Robson, Mark E.
    Iwata, Hiroji
    Hegg, Roberto
    Nechaeva, Marina
    Xu, Binghe
    Verma, Sunil
    Haddad, Vincent
    Imedio, Esteban Rodrigo
    Schiavon, Gaia
    Foxley, Andrew
    Park, Yeon Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345